Sino Biopharmaceutical ( ($HK:1177) ) has provided an update. Sino Biopharmaceutical has reported positive Phase II clinical trial results for ...

Psoriasis is a serious skin disease caused by a weakened immune system. It causes red, scaly patches to form on the skin. It ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...

Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and ...

In a surprising new study, scientists from Ewha Woman’s University have found a possible link between common blood pressure ...

Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...

In the last Fierce Pharma Asia weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval for ...

Shares of Takeda Pharmaceuticals rose after the Japanese pharmaceutical major announced positive results from clinical trials of its new treatment for plaque psoriasis. The stock climbed 4.3% in early ...

Patients with moderate-to-severe plaque psoriasis who took the once-daily pill showed significantly clearer skin compared with those on placebo or the existing therapy apremilast, the company said.